Loading organizations...
Based in Philadelphia, Pennsylvania, BioPhy develops predictive and generative artificial intelligence software designed to analyze clinical trial data, forecast drug development outcomes, and automate regulatory compliance processes. The company's proprietary platform, BioLogicAI, evaluates the scientific and commercial viability of experimental therapeutics, historically predicting clinical trial success rates with over 80 percent accuracy across thousands of studies. This enterprise software is utilized by major biopharmaceutical companies and nonprofit organizations, featuring strategic technology partnerships with Every Cure and Ambrose Healthcare to support drug repurposing and preclinical benchmarking initiatives. BioPhy has raised $11.11 million in total funding across multiple venture capital rounds, securing financial backing from investment firms such as Metrodora Ventures, Macanta Investments, and Audere Capital. The software business was officially established in 2019 by co-founders Dave Latshaw II, Steve Truong, Daniel Sciubba, and Daniel Fisher.
BioPhy has raised $5.0M across 1 funding round.
BioPhy has raised $5.0M in total across 1 funding round.
BioPhy has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $5M Seed | — | Metrodora Ventures | Announced |
BioPhy has raised $5.0M in total across 1 funding round.
BioPhy's investors include Metrodora Ventures.
BioPhy is a Philadelphia-based healthcare technology company founded in 2019 that builds an AI platform to accelerate drug development and optimize pharmaceutical operations.[1][2][3] Its core product, BioLogicAI, uses predictive AI to analyze clinical trial data, forecast outcomes with 80%+ accuracy, assess biological feasibility, and guide decisions from pre-clinical stages through regulatory approval, serving biopharma companies to reduce trial failures (95% industry rate), cut costs, and speed therapies to market.[1][2][3][4] The platform also includes BioPhyRx and modular AI tools for clinical operations, regulatory compliance, quality assurance, manufacturing, supply chain, and more, addressing inefficiencies like lengthy trials and high financial burdens.[3][4][5] BioPhy has raised Series A funding, works with top-10 pharmas and partners like Ambrose Healthcare, and earned Fast Company's 2024 World Changing Ideas award for democratizing AI to empower underfunded teams.[1][3][4]
BioPhy was co-founded in 2019 by Dave Latshaw II, PhD, MBA, a computational biomolecular and chemical engineer who previously led AI deployments across 20+ programs at Johnson & Johnson's Advanced Technologies Center of Excellence, impacting $16B in annual sales with 20% cost reductions and 50% reliability gains—work recognized by the World Economic Forum, McKinsey, and the National Academy of Engineering.[1][4] The idea emerged from Latshaw's experience tackling drug development's systemic inefficiencies, like 95% trial failure rates and massive costs, using AI to predict outcomes and automate processes.[2][3][4] Early traction came from live testing over 27 months on 1,500+ trials achieving 80% accuracy, validated third-party, leading to partnerships with leading pharmas and expansions into regulatory and operations AI.[1][4] Headquartered at 1650 Market Street in Philadelphia, BioPhy has grown via Series A funding and accolades like Fast Company's recognition.[1][3]
BioPhy rides the AI-for-drug-discovery wave, targeting pharma's $2T+ market where 95% of candidates fail trials due to poor predictions, long timelines (10+ years), and $2B+ costs per drug.[2][3] Timing aligns with explosive AI adoption post-ChatGPT, regulatory shifts favoring digital tools (e.g., FDA's AI pilots), and post-pandemic supply chain strains, enabling modular solutions for compliance and ops amid talent shortages.[3][4][5] Market forces like rising biotech funding needs and investor demands for derisked portfolios favor BioPhy's 80% accuracy in forecasting, influencing the ecosystem by accelerating viable therapies, cutting waste, and leveling the field for underfunded innovators—earning "World Changing Ideas" status.[1][3] As a leader in clinical trial analytics (per CB Insights ESP matrix), it benchmarks against IQVIA/Oracle, pushing pharmas toward AI-native R&D.[1]
BioPhy's momentum—Series A, top-pharma clients, and validated accuracy—positions it for Series B/expansion into generative AI for drug design and global regulatory tools, potentially capturing share in the $50B+ clinical analytics market.[1][4] Trends like multimodal AI (integrating omics/clinical data) and real-world evidence will amplify its edge, while pharma's $100B+ annual AI spend fuels growth amid talent wars.[5] Its influence may evolve from niche predictor to full-stack AI OS, enabling 2-3x faster approvals and broader access to therapies, ultimately slashing industry failure rates and investor risks—transforming how we predict and deliver life-saving drugs.[3][4]
